表紙
市場調査レポート

門脈圧亢進症:パイプライン製品の分析

Portal Hypertension - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 213081
出版日 ページ情報 英文 73 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.39円で換算しております。
Back to Top
門脈圧亢進症:パイプライン製品の分析 Portal Hypertension - Pipeline Review, H1 2016
出版日: 2016年03月30日 ページ情報: 英文 73 Pages
概要

門脈圧亢進症は、門脈系と呼ばれる静脈系で、血圧が上昇することです。症状は、腹水、血小板や白血球のレベル低下、消化管出血、脳症、錯乱や健忘症などが見られます。門脈圧亢進症の最も多い原因は、肝硬変です。

当レポートでは、門脈圧亢進症に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向などについて、体系的な情報を提供しています。

目次

イントロダクション

門脈圧亢進症の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

パイプライン製品の概要

  • 臨床段階の製品
  • 初期段階の製品

開発中の製品:企業別

治療薬の開発に従事している企業

  • Conatus Pharmaceuticals Inc.
  • Intercept Pharmaceuticals, Inc.
  • Mezzion Pharma Co. Ltd.
  • 小野薬品工業
  • Phenex Pharmaceuticals AG

治療薬の評価

  • 単独療法の場合
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

  • emricasan
  • obeticholic acid
  • ONO-1266
  • PX-20606
  • udenafil

パイプライン製品の最新動向

開発休止中のプロジェクト

開発が中止されたプロジェクト

製品開発のマイルストーン

  • 注目のニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7783IDB

Summary

Global Markets Direct's, 'Portal Hypertension - Pipeline Review, H1 2016', provides an overview of the Portal Hypertension pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Portal Hypertension, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Portal Hypertension and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Portal Hypertension
  • The report reviews pipeline therapeutics for Portal Hypertension by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Portal Hypertension therapeutics and enlists all their major and minor projects
  • The report assesses Portal Hypertension therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Portal Hypertension

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Portal Hypertension
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Portal Hypertension pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Portal Hypertension Overview
  • Therapeutics Development
    • Pipeline Products for Portal Hypertension - Overview
  • Portal Hypertension - Therapeutics under Development by Companies
  • Portal Hypertension - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Portal Hypertension - Products under Development by Companies
  • Portal Hypertension - Companies Involved in Therapeutics Development
    • Conatus Pharmaceuticals Inc.
    • Galectin Therapeutics, Inc.
    • Gilead Sciences, Inc.
    • Intercept Pharmaceuticals, Inc.
    • LinXis B.V.
    • Mezzion Pharma Co. Ltd.
    • Ono Pharmaceutical Co., Ltd.
  • Portal Hypertension - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • emricasan - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GRMD-02 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GS-9674 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LIN-003 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • obeticholic acid - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ONO-1266 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • udenafil - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Portal Hypertension - Recent Pipeline Updates
  • Portal Hypertension - Dormant Projects
  • Portal Hypertension - Discontinued Products
  • Portal Hypertension - Product Development Milestones
    • Featured News & Press Releases
      • Oct 20, 2015: Conatus Pharmaceuticals Announces Acceptance of Late-Breaking Abstract for AASLD Annual Meeting
      • Sep 23, 2015: Conatus Announces Top-line Results From Multicenter Phase 2 Portal Hypertension Clinical Trial in Patients With Liver Cirrhosis
      • Nov 10, 2014: Conatus Pharmaceuticals Presents Late-Breaking Poster At AASLD Annual Meeting
      • Oct 08, 2014: Conatus Pharmaceuticals Announces Acceptance Of Late-Breaking Abstract For AASLD Annual Meeting
      • Sep 02, 2014: Conatus Pharmaceuticals Initiates Phase 2 Trial in Patients with Liver Cirrhosis and Separate Open Label Phase 2 Trial in Cirrhosis Patients with Portal Hypertension
      • Nov 08, 2012: Intercept Pharma To Present Phase IIa Portal Hypertension Data At AASLD's Annual Liver Meeting
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Portal Hypertension, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Portal Hypertension - Pipeline by Conatus Pharmaceuticals Inc., H1 2016
  • Portal Hypertension - Pipeline by Galectin Therapeutics, Inc., H1 2016
  • Portal Hypertension - Pipeline by Gilead Sciences, Inc., H1 2016
  • Portal Hypertension - Pipeline by Intercept Pharmaceuticals, Inc., H1 2016
  • Portal Hypertension - Pipeline by LinXis B.V., H1 2016
  • Portal Hypertension - Pipeline by Mezzion Pharma Co. Ltd., H1 2016
  • Portal Hypertension - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Portal Hypertension Therapeutics - Recent Pipeline Updates, H1 2016
  • Portal Hypertension - Dormant Projects, H1 2016
  • Portal Hypertension - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Portal Hypertension, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top